Patient-reported outcomes in dose-finding show value in oncology trial inclusion, but shared standards are needed
Findings from studies show that patient-centred evidence can inform decisions in early-phase cancer research
Can AI help deliver better medicines to patients?
Artificial intelligence has entered drug discovery and development supporting target identification and validation, but challenges remain
Garassino: “Bridging cultures has shaped my career as a female oncologist”
Reflecting on her transatlantic journey from Italy to the United States of America, Prof. Marina Chiara Garassino shares the key lessons that continue to influence her leadership style
ctDNA testing may help refine surveillance strategy for colorectal cancer
Study findings show that ctDNA is a stronger biomarker than carcinoembryonic antigen to select patients who may benefit from metastasis-directed therapy
Promising activity reported for olaparib in advanced biliary tract cancers
Study indicates that PARP inhibition could extend treatment options for patients with biliary tract cancers
Prolonged intertreatment interval improves outcomes to EGFR rechallenge in metastatic colorectal cancer
Randomised trials and real-world data propel the anti-EGFR rechallenge approach towards standard of care, but more solid evidence is needed
ctDNA and RNA-based tests are expanding colorectal cancer screening options
The availability of simpler, less-invasive methodologies may help to encourage participation in secondary prevention programmes
Quality of Life data in immune oncology trials: from side note to centre stage?
Despite greater attention being given to treatment effects on patient wellbeing, the high heterogeneity of methodologies still limits the usefulness of QoL assessment
Atezolizumab and bevacizumab after transarterial chemoembolisation prolongs progression-free survival in unresectable hepatocellular carcinoma
Data from the TALENTACE trial add to growing evidence supporting the combination of immunotherapy plus anti-VEGF component with TACE
Decoding genomic and transcriptomic signatures in colorectal cancer – next steps?
Newer technologies build on current knowledge to provide greater insights in the molecular landscape